Articles
RIP big pharma drug development?

RIP big pharma drug development?

Is the current big pharma drug development model dead and buried or just resting? pharmaphorum speaks with international expert Dr Kenneth Kaitin for some answers. In years gone by the drug development process seemed to function like a well-oiled machine, with investment fuelling the research at one end of...

Articles
Marketing rationales to avoid in 2011 (part II)

Marketing rationales to avoid in 2011 (part II)

In the second of her two part series on marketing rationales, Andree Bates gives tips on how to make rational marketing decisions. All people, even marketers, are subject to irrationality. It's not a question of how smart you are, but of having evolved in an environment where impulsive actions kept us alive. Hunter-gatherers who…

Articles
Patients can inspire the industry to innovate

Patients can inspire the industry to innovate

Can patient communities provide useful information directly to pharma and not just each other? Brian Loew, Founder of Inspire, explains to pharmaphorum how they can. As information becomes much more readily available and patients are able to connect with each other through social networks, many disease areas...

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Editor's Picks

  1. UK budget includes £1bn biopharma investment package
  2. HHS doubles down on controversial peptides plan
  3. Lilly's triple G overpowers Ozempic in diabetes trial
  4. UK puts £100m into "world-first" AI biosecurity facility
  5. US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more